Is InflaRx NV halal to invest in?

According to Musaffa's Shariah screening methodology, InflaRx NV (IFRX) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is InflaRx NV a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes InflaRx NV using these criteria to determine its compliance status.

Can Muslims buy shares of InflaRx NV?

Muslim investors may consider investing in InflaRx NV if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is InflaRx NV classified as NOT HALAL?

Musaffa determines the Shariah status of InflaRx NV by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for InflaRx NV updated?

The Shariah compliance status of InflaRx NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like InflaRx NV become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of InflaRx NV?

You can check the latest Shariah compliance status of InflaRx NV on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

IFRX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: December 06, 2025

Report Source: 2025 3rd Quarter Report

Analyst's Ratings for InflaRx NV (IFRX)

Based on 14 analysts giving stock ratings to InflaRx NV in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

InflaRx NV. Stock Analysis IFRX

United States Health Care Micro Cap Report: Q3, 2025

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 65 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

Key Statistics of InflaRx NV (IFRX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$2.25$2.48

Today's Open

$2.38

Volume

1.45M

P/E Ratio (TTM)

52 Week Range

$0.71$2.95

Market Cap

142.42M

Avg. Volume

3.34M

Dividend Yield

Financial Metrics & Statements of InflaRx NV (IFRX)

FAQ's for InflaRx NV (IFRX)

According to Musaffa’s Shariah screening methodology, InflaRx NV (IFRX) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.